Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NYSE:AORT

Artivion (AORT) Stock Price, News & Analysis

Artivion logo
$23.03 -0.27 (-1.15%)
Closing price 03:59 PM Eastern
Extended Trading
$22.98 -0.05 (-0.23%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Artivion Stock (NYSE:AORT)

Advanced

Key Stats

Today's Range
$22.91
▼
$23.63
50-Day Range
$21.18
▼
$28.90
52-Week Range
$19.16
▼
$48.25
Volume
366,021 shs
Average Volume
496,854 shs
Market Capitalization
$1.12 billion
P/E Ratio
43.15
Dividend Yield
N/A
Price Target
$42.86
Consensus Rating
Moderate Buy

Company Overview

Artivion, Inc. (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care. Based in Kennesaw, Georgia, the company serves hospitals, surgeons, and patients in the United States and international markets. Patrick S. Mackin has served as the company’s chairman, president, and chief executive officer.

AI Generated. May Contain Errors.

Artivion Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

AORT MarketRank™: 
3.666666666665 of 5 stars

Artivion scored higher than 73% of companies evaluated by MarketBeat, and ranked 214th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artivion has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Artivion has a consensus price target of $42.86, representing about 86.1% upside from its current price of $23.03.

  • Amount of Analyst Coverage

    Artivion has only been the subject of 3 research reports in the past 90 days.

  • Read more about Artivion's stock forecast and price target.
  • Earnings Growth

    Earnings for Artivion are expected to grow by 71.11% in the coming year, from $0.45 to $0.77 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artivion is -329.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artivion is -329.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artivion has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Artivion's valuation and earnings.
  • Percentage of Shares Shorted

    8.18% of the float of Artivion has been sold short.
  • Short Interest Ratio / Days to Cover

    Artivion has a short interest ratio ("days to cover") of 7.22.
  • Change versus previous month

    Short interest in Artivion has recently increased by 3.15%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Artivion does not currently pay a dividend.

  • Dividend Growth

    Artivion does not have a long track record of dividend growth.

  • News Sentiment

    Artivion has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Artivion this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for AORT on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Artivion to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,557,366.00 in company stock.

  • Percentage Held by Insiders

    6.30% of the stock of Artivion is held by insiders.

  • Percentage Held by Institutions

    86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Artivion's insider trading history.
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AORT Stock News Headlines

Artivion (NYSE:AORT) Research Coverage Started at Jefferies Financial Group
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
Jefferies Initiates Artivion at Buy With $31 Price Target
Artivion (AORT) Stock May Be 13% Undervalued On Cash Flow
Artivion, Inc. (NYSE:AORT) Stock Has Consensus Target Price of $44.83
See More Headlines

AORT Stock Analysis - Frequently Asked Questions

Artivion's stock was trading at $45.71 on January 1st, 2026. Since then, AORT stock has decreased by 49.6% and is now trading at $23.0330.

Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Thursday, August, 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.00 by $0.13. The company earned $125.76 million during the quarter, compared to analysts' expectations of $119.99 million. Artivion had a positive trailing twelve-month return on equity of 6.07% and a negative net margin of 0.67%.
Read the conference call transcript
.

Artivion's top institutional shareholders include Inspire Investing LLC (0.06%), State of Alaska Department of Revenue (0.03%), Yousif Capital Management LLC (0.03%) and Versant Capital Management Inc. Insiders that own company stock include James P Mackin, John E Davis, Lance A Berry, Jean F Holloway, Amy Horton, Marshall S Stanton, Andrew M Green, Rochelle L Maney, Matthew A Getz, Anthony B Semedo and Elizabeth A Hoff.
View institutional ownership trends
.

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Rocket Lab (RKLB), Tesla (TSLA), Salesforce (CRM), Vertiv (VRT) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/06/2026
Today
10/26/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:AORT
CIK
784199
Employees
1,800
Year Founded
1984

Price Target and Rating

High Price Target
$50.00
Low Price Target
$31.00
Potential Upside/Downside
+86.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.07)
Trailing P/E Ratio
43.15
Forward P/E Ratio
51.18
P/E Growth
N/A
Net Income
$9.77 million
Net Margins
-0.67%
Pretax Margin
0.47%
Return on Equity
6.07%
Return on Assets
2.93%

Debt

Debt-to-Equity Ratio
0.82
Current Ratio
3.47
Quick Ratio
2.51

Sales & Book Value

Annual Sales
$441.33 million
Price / Sales
2.54
Cash Flow
$1.09 per share
Price / Cash Flow
21.15
Book Value
$9.46 per share
Price / Book
2.43

Miscellaneous

Outstanding Shares
48,760,000
Free Float
45,684,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.23

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NYSE:AORT) was last updated on 10/26/2026 by MarketBeat.com Staff.
From Our Partners